/
DSGN
$14.24+$0.89 (+6.67%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$833.8M
62M shares
52-week range
$3.33 – $17.25
78% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.50%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-5.65
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $834 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $1.7K | $5.0K | $0 | $466.0K | $537.0K | $596.0K | $622.0K |
| Gross profit | −$820 | −$5.0K | $0 | −$466.0K | −$537.0K | −$596.0K | −$622.0K |
| Gross margin | -98.3% | — | — | — | — | — | — |
| R&D | $1.7M | $6.1M | $24.8M | $48.6M | $57.1M | $44.4M | $59.1M |
| Operating income | −$1.9M | −$8.6M | −$35.8M | −$67.6M | −$78.2M | −$62.4M | −$79.5M |
| EBITDA | −$139.0K | −$8.3M | −$35.4M | −$62.8M | −$66.3M | −$49.0M | −$69.2M |
| Net income | −$2.0M | −$8.3M | −$35.5M | −$63.3M | −$66.9M | −$49.6M | −$69.8M |
| Net margin | -245443.6% | — | — | — | — | — | — |
| EPS (diluted) | -0.08 | -0.30 | -0.77 | -1.14 | -1.19 | -0.88 | -1.22 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $117M | $-1.36 | $-1.63–$-1.17 | 5 |
| 2027 | $205M | $-1.64 | $-1.96–$-1.34 | 5 |
| 2028 | $8M | $-1.95 | $-2.41–$-1.41 | 5 |
| 2029 | $72M | $-1.50 | $-1.50–$-1.50 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.26
Price
$14.24
Implied downside
-98%
Peer comparison
Design Therapeutics, Inc. Common Stock
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
www.designtx.com- Employees
- 54
- IPO / List date
- Mar 26, 2021
- HQ
- CARLSBAD, CA
Held by traders on TradeandTell
No one on the platform currently holds DSGN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 408,200 | $4.3M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded DSGN yet.
